FDA Gives Its Approval of enVista

The U.S. Food and Drug Administration (FDA) has approved the enVista hydrophobic acrylic intraocular lens (IOL), announced Bausch + Lomb. The lens is the first and only FDA-approved IOL in the U.S. with labeling that states: "No glistenings of any grade were reported for any subject at any visit in the clinical study," notes B+ L. Glistenings are fluid-filled microvacuoles that can form within an IOL and are common in some hydrophobic acrylic IOLs. Glistenings may not only present an aesthetic issuebut could impact visual function, including visual acuity and contrast sensitivity in patients, because a portion of light coming into the eye could be scattered. Read more.

B+L Introduces New Products at the Vienna Conference

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV) will introduce the Victus Femtosecond Laser Platform at the upcoming XXIX Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2011). The platform is a first-of-its-kind technology, capable of supporting cataract, refractive and therapeutic procedures in a single platform. The versatile platform is designed to enable greater precision compared to manual cataract surgery techniques, potentially enhancing the patient experience.Read more.


At the same conference, B+L will introduce "its new enVista glistening-free, hydrophobic acrylic intraocular lens," according to a post on Sys-Con. The lens reportedly "represents a significant step forward in IOL technology. Setting the enVista apart from currently available IOLs is the unique combination of aspheric, aberration-free Advanced Optics technology, designed to deliver enhanced contrast sensitivity and better vision quality, with a clinically proven glistening-free material. In addition, the enVista lens design is intended to minimize posterior capsular opacification (PCO), a common long-term problem with IOLs that can cause patient vision to become clouded post-surgery." Read more.